Table 4: Results of the sensitivity and scenario analyses: difference in % versus the market price.
| PHN | Hunter syndrome | CF | CF | PBC | SMA | CLN2 | Alpha-man. Lys. | Lipo Dys. | |
| Eculizumab | Idursulfase | Lumacaftor/Ivacaftor | Ataluren | €200.000 - €800.000 | |||||
| Price | €358,000 | €600,000 | €169,386 | €270,000 | €38,021 | €240,000 | €595,971 | €800,000 | €480,000 |
| Break-even price base case | -22%* | -44% | 157% | 6% | -19% | 150% | -25% | 0% | -6% |
| Cost of capital 9% | -1% | -29% | 225% | 34% | 3% | 217% | -6% | 27% | 21% |
| Cost of capital 18% | -58% | -70% | 39% | -43% | -56% | 35% | -60% | -46% | -51% |
| Include non-Western markets | 40% | 0% | 363% | 91% | 47% | 351% | 34% | 80% | 69% |
| Reimbursement 80% | -41% | -58% | 183% | -20% | -39% | 88% | -44% | -25% | -29% |
| Failures: 20% higher | -60% | -71% | 32% | -45% | -58% | 29% | -62% | -49% | -52% |
| Costs 20% R&D lower | -17% | -35% | 202% | 25% | -4% | 193% | -12% | 18% | 11% |
| Costs 20% R&D higher | -36% | -56% | 101% | -17% | -36% | 96% | -42% | -22% | -26% |
| Cost sales 20% lower | -29% | -41% | 174% | 13% | 13% | 167% | -21% | 7% | 0% |
| Cost sales 20% higher | -36% | -55% | 110% | -14% | -34% | 104% | -39% | -19% | -23% |
| Delay | -37% | -55% | 107% | -14% | -34% | 102% | -40% | -19% | -25% |
| Drug price 30% higher | 9% | -22% | 258% | 48% | 13% | 249% | 4% | 39% | 31% |
| Uptake 60-70-80% | -28% | -50% | 129% | -5% | -27% | 98% | -34% | -11% | -2% |
| Uptake 70-80-95% | -15% | -41% | 171% | 12% | -14% | 134% | -22% | 5% | 15% |
*A positive difference indicates that actual prices are higher than break-even prices and a negative difference indicates that actual prices are lower than break-even prices.